Brought to you by:
RESCUE trial shows reduction in segmental and main pulmonary artery occlusions
Robert A. Lookstein, MD, who is executive vice chair, Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai Hospital in New York today presented the results of a subanalysis of Thrombolex’s National Heart, Lung and…
‘SVS Presents’ provides enhanced learning opportunities
The Society for Vascular Surgery (SVS) will debut “SVS Presents” April 12, a monthly webinar series that provides an evening of educational programming for members. “Presents” is in response to a key finding from the 2021 Educational Needs Assessment and…
AVF 2023: Results from first US trial of Sonovein delivered
The 2023 annual meeting of the American Venous Forum (AVF) heard the final results from the first U.S. trial of the emerging varicose vein treatment, Sonovein echotherapy, with data showing a 100% technical feasibility at three months—which was the principal…
The top 10 most popular Vascular Specialist stories of February 2023
In February 2023, the hits with Vascular Specialist readers included positive safety and efficacy findings from the PRESERVE trial; the announcement of the scientific program for Sudan’s first vascular meeting; the release of a former Society for Vascular Surgery (SVS) President’s…
VESS 2023: pMAC score found to be ‘important predictor’ of CLTI revascularization outcomes
Having observed a strong relationship between calcification and subsequent limb loss, a research team led by investigators from the University of California San Francisco (UCSF) have conducted a single-center, retrospective follow-up extending an initial study evaluating pedal medial arterial calcification…
AVF 2023: FLASH registry suggests ‘favorable safety and effectiveness profile’ in high-risk PE patients
Among 61 high-risk pulmonary embolism (PE) patients followed through to the 30-day visit in the U.S. cohort of the FLASH registry, no mortalities were recorded, while at 48 hours post-treatment with the FlowTriever mechanical embolectomy system, likewise, there were no…
AVF 2023: Investigators report update on three-year first-in-human results for bioprosthetic venous valve
Researchers in Colombia behind the first-in-human study of a novel bioprosthetic venous valve designed to treat chronic venous insufficiency (CVI) reported three-year results among eight patients during the 2023 annual meeting of the American Venous Forum (Feb. 22–25) in San…
AVF 2023: One-year analysis of CLOUT registry reveals ‘significant and sustained’ long-term clinical improvements
Interim one-year outcomes from the multicenter, prospective, single-arm CLOUT registry investigating use of the ClotTriever thrombectomy system in all-comer patients with deep vein thrombosis (DVT) demonstrated that 93.5% of limbs had flow present, 97.1% were compressible and 10.5% of patients…
New study demonstrates IVC filters ‘safe and effective’ in treating venous thromboembolism
Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the safety and effectiveness of inferior…
‘Urgent action needed’ to improve implementation of guideline-directed medical therapy for PVI
Almost one-half of the patients receiving a peripheral vascular intervention (PVI) in the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry between 2017 and 2018 were not on guideline-directed medical therapy (GDMT). Kim G. Smolderen, PhD, and Carlos…